Cysteamine therapy: a treatment for cystinosis, not a cure.

نویسنده

  • Stephanie Cherqui
چکیده

Cystinosis as a clinical entity is a progressive dysfunction of multiple organs caused by the accumulation of cystine in the tissues, leading, for example, to end-stage renal failure, diabetes, hypothyroidism, myopathy, and central nervous system deterioration. Brodin-Sartorius and colleagues present a long-term study on the impact of cysteamine therapy on these complications. The data show that cysteamine improves the outcome and complications of cystinosis but does not prevent them.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Nephropathic Cystinosis: Symptoms, Treatment, and Perspectives of a Systemic Disease

Cystinosis is a rare autosomal recessive lysosomal storage disorder caused by mutations in the CTNS gene. Main dysfunction is a defective clearance of cystine from lysosomes that leads to accumulation of cystine crystals in every tissue of the body. There are three different forms: infantile nephropathic cystinosis, which is the most common form, juvenile nephropatic, and non-nephropathic cysti...

متن کامل

Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy.

BACKGROUND The full burden of nephropathic cystinosis in adulthood and the effects of long-term oral cysteamine therapy on its nonrenal complications have not been elucidated. OBJECTIVE To assess the severity of cystinosis in adults receiving and not receiving oral cysteamine therapy. DESIGN Case series. SETTING National Institutes of Health Clinical Center. PATIENTS 100 persons (58 men...

متن کامل

BRIEF REPORT Treatment of cystinosis with delayed-release cysteamine: 6-year follow-up

Background Patients with nephropathic cystinosis are required to take 6-hourly immediate-release cysteamine (Cystagon®) to reduce disease progression. This arduous regimen affects quality of life, disrupts sleep, and may result in noncompliance with therapy. Enteric-coated cysteamine bitartrate (EC-cysteamine) was developed as a “proof-of-concept” formulation for twice-daily ingestion. Previous...

متن کامل

A cost-effectiveness analysis of the orphan drug cysteamine in the treatment of infantile cystinosis.

OBJECTIVE Cysteamine is a recently licensed orphan drug used to treat the inherited metabolic disease cystinosis. The drug delays the onset of renal failure in cystinotic patients and may provide many other significant health benefits. This study examined the cost-effectiveness of the administration of cysteamine to cystinotic patients prior to end-stage renal disease (ESRD). METHOD Decision-...

متن کامل

Long-term treatment of cystinosis in children with twice-daily cysteamine.

OBJECTIVE Cystinosis causes renal and other organ failure. Treatment with 6-hourly cysteamine bitartrate (Cystagon, Mylan, Morgantown, West Virginia) reduces intracellular cystine and the rate of organ deterioration. A recent study showed that an enteric-release cysteamine required less frequent daily dosing. This report describes the long-term use of enteric-coated (EC) cysteamine bitartrate (...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Kidney international

دوره 81 2  شماره 

صفحات  -

تاریخ انتشار 2012